Tower Research Capital (TRC)’s BioLineRX BLRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$425 Buy
+181
New +$499 ﹤0.01% 5575
2025
Q4
– Sell
-39
Closed -$147 – 5163
2025
Q3
$147 Buy
+39
New +$156 ﹤0.01% 5090
2022
Q3
– Sell
-18
Closed -$1K – 6066
2022
Q2
$1K Buy
+18
New +$1K ﹤0.01% 5738
2016
Q1
– Sell
-3
Closed -$2K – 4131
2015
Q4
$2K Buy
+3
New +$2.49K ﹤0.01% 3689
2015
Q1
– Hold
0
– – – 4409
2014
Q4
– Sell
-7
Closed -$6.08K – 4028
2014
Q3
$7K Buy
+7
New +$7.52K ﹤0.01% 3056
2014
Q1
– Sell
-17
Closed -$28K – 4447
2013
Q4
$28K Buy
17
+14
+467% +$22.6K ﹤0.01% 1950
2013
Q3
$4K Buy
+3
New +$3.54K ﹤0.01% 3771

Other funds holding BLRX

Tower Research Capital (TRC)'s BLRX Position: Q3 2026 in Review

Tower Research Capital (TRC) opened a new position in BioLineRX (BLRX) in Q3 2026: 181 shares worth $425. The stake represents ﹤0.01% of the portfolio and ranks #5575 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in BLRX as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in BLRX in Q3 2013 and has held it in 7 quarters since. The position peaked at $28K in Q4 2013. 17 funds tracked by Wall St. Rank hold BLRX as of Q3 2026.

  • Tower Research Capital (TRC) held 181 shares of BioLineRX worth $425 as of Q3 2026.
  • BioLineRX was a new Tower Research Capital (TRC) position in Q3 2026.
  • BioLineRX made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #5575 holding.
  • Tower Research Capital (TRC) first reported a position in BioLineRX in Q3 2013 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s BioLineRX position peaked at $28K in Q4 2013.
  • 17 funds tracked by Wall St. Rank held BioLineRX as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.